On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Hosted on MSN17h
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same PageShares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...
B Health and two hospitals seek to intervene in Eli Lilly lawsuit, saying proposed rebate model would burden hospitals with ...
Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech found success with a different B cell-killing ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback